Consistent with the reduced olaparib‐induced PARP1 trapping in the presence of HMGA2, silencing HMGA2 was required to significantly reduce cell viability in our tumor cell models upon olaparib treatment in MMS exposed cells. This evidence concerns the gene HMGA2 and neoplasm.